NCT04674241

Dexmedetomidine Alleviates Postoperative Delirium After Brain Tumor Resections

Effect of Dexmedetomidine on Postoperative Delirium in Patients Undergoing Brain Tumor Resections: a Randomized Controlled Study

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 260 (actual)
• Sponsor: Beijing Tiantan Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Postoperative delirium (POD) is a common complication, and the incidence rate is about 25% in non cardiac surgery. Previous studies have reported that the total incidence of neurological pod ranged from 10% to 22%. Dexmedetomidine (DEX) is an a-2 adrenergic agonist for sedation. This kind of drug has little effect on respiratory function, is easy to wake up and has analgesic effect. It is a commonly used perioperative adjuvant drug. However, for neurosurgical patients with brain tumors, the role of DEX in POD is not clear. The purpose of this study was to investigate the effect of DEX on POD in neurosurgical brain tumor surgery.

Conditions

• Dexmedetomidine
• Postoperative Delirium

Interventions

Type	Name	Description
DRUG	Dexmedetomidine	Ten minutes after anesthesia induction and endotracheal intubation, patients assigned to dexmedetomidine group were given a loading dose of dexmedetomidine 0.6 μg/kg over 10 minutes, followed by continuous infusion at a rate of 0.4 μg/kg/h until the start of dural closure.
DRUG	0.9% saline	0.9% saline is administered with the same volume at the same speed as the other group.

Timeline

• Start date: 2021-01-18
• Primary completion: 2021-12-31
• Completion: 2022-01-28
• First posted: 2020-12-19
• Last updated: 2022-04-04

Locations

2 sites across 1 country: China